Glaxosmithkline
GlaxoSmithKline plc (GSK), a leading global healthcare company headquartered in Great Britain, has been at the forefront of pharmaceutical innovation since its founding in 2000, following the merger of Glaxo Wellcome and SmithKline Beecham. With a strong presence in Europe, North America, and emerging markets, GSK operates primarily in the pharmaceutical, vaccine, and consumer healthcare sectors. The company is renowned for its diverse portfolio, which includes groundbreaking medicines, vaccines, and consumer health products that address a wide range of health needs. GSK's commitment to research and development has led to significant advancements in areas such as respiratory diseases, HIV, and immunology. As a key player in the global healthcare landscape, GSK continues to achieve notable milestones, reinforcing its position as a trusted provider of innovative health solutions.
DitchCarbon Score
How does Glaxosmithkline's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glaxosmithkline's score of 82 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Glaxosmithkline's reported carbon emissions
In 2023, GlaxoSmithKline (GSK) reported carbon emissions of approximately 102,000,000 kg CO2e for Scope 1 and 2 combined in Great Britain. This figure reflects GSK's ongoing commitment to reducing its greenhouse gas emissions. The company has set ambitious targets, aiming for a 34% reduction in absolute Scope 1 and 2 emissions by 2025 from a 2017 baseline. Additionally, GSK plans to cut its absolute Scope 3 emissions by 16% by 2030, also from a 2017 base year. Looking further ahead, GSK has committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2045, with interim targets of an 80% reduction in Scope 1 and 2 emissions by 2030 and a 90% reduction by 2045, both from a 2020 baseline. The company also aims for a similar 90% reduction in Scope 3 emissions by 2045. GSK's climate strategy aligns with the Science Based Targets initiative (SBTi), ensuring that its targets are consistent with the global goal of limiting temperature rise to 1.5°C. This comprehensive approach underscores GSK's dedication to sustainability and its proactive stance in addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glaxosmithkline is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
